<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520932</url>
  </required_header>
  <id_info>
    <org_study_id>RFANET-IPC 2020-003</org_study_id>
    <nct_id>NCT04520932</nct_id>
  </id_info>
  <brief_title>Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors</brief_title>
  <acronym>RFANET</acronym>
  <official_title>Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Low Grade Pancreatic Neuroendocrine Tumors of Less Than 2cm in Size</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring&#xD;
      of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs&#xD;
      (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small&#xD;
      studies have evaluated this treatment and the results are encouraging. It appears necessary&#xD;
      to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA&#xD;
      applied to PNETs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the efficacy of radiofrequency treatment of&#xD;
      grade 1 NF-PNETS with a size less than or equal to 2cm.&#xD;
&#xD;
      Patients meeting the selection criteria will be included in the study after signing the&#xD;
      consent. They will benefit from a RFA treatment consisting of 1 to 3 sessions depending on&#xD;
      their response to the treatment. Patients will then be followed for 5 years in order to&#xD;
      evaluate their response to treatment, their clinical evolution, their quality of life and any&#xD;
      complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">April 2031</completion_date>
  <primary_completion_date type="Anticipated">April 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response</measure>
    <time_frame>1 year</time_frame>
    <description>Complete response rate to radiofrequency treatment defined by the absence of enhancement with the contrast agent and/or the disappearance of the lesion on imaging.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Neuroendocrine Tumor of Pancreas (Disorder)</condition>
  <condition>Neuroendocrine Tumor Grade 1</condition>
  <arm_group>
    <arm_group_label>RFA treatment efficacy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PNETs ablation by radiofrequency treatment (1 to 3 sessions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from TaewongÂ®.</description>
    <arm_group_label>RFA treatment efficacy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;&#xD;
&#xD;
          -  Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with&#xD;
             Ki67&lt;3%,&#xD;
&#xD;
          -  Non-secretory lesion.&#xD;
&#xD;
          -  Homogeneous HEE contrast taking;&#xD;
&#xD;
          -  No positron emission tomography (PET) FDG binding to the pancreatic mass;&#xD;
&#xD;
          -  Lesion &lt;20mm on conventional imaging at 6 months monitoring;&#xD;
&#xD;
          -  Age 18 to 80 years inclusive;&#xD;
&#xD;
          -  Patient in good general condition, World Health Organization [0-1];&#xD;
&#xD;
          -  Signed consent to participate;&#xD;
&#xD;
          -  Affiliation to healthcare insurance system or beneficiary of this regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or likely to become pregnant (without effective contraception) or&#xD;
             breastfeeding ;&#xD;
&#xD;
          -  A person in an emergency situation or deprived of liberty or placed under the&#xD;
             authority of a tutor.&#xD;
&#xD;
          -  Life expectancy &lt; 1 year;&#xD;
&#xD;
          -  Severe hemostasis disorders;&#xD;
&#xD;
          -  Pancreatic and/or biliary ductal dilation;&#xD;
&#xD;
          -  Lesion considered to be adjacent to the pancreatic duct and/or bile duct;&#xD;
&#xD;
          -  Node extension and/or metastatic disease;&#xD;
&#xD;
          -  Patient being managed for another malignant lesion which is progressive or under&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice CAILLOL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paoli Calmettes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GENRE Dominique, MD</last_name>
      <phone>+ 33 4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>GOUARNE Caroline, PhD</last_name>
      <phone>+ 33 4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radio Frequency treatment</keyword>
  <keyword>Echoendoscopy</keyword>
  <keyword>Ablation</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

